Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795897 | 0.92 | F2R (0.64) | F2RCNR1TMEM97PROKR1KDM4E | |
| SCHEMBL9894509 | 0.88 | F2R (0.56) | F2RCNR1TMEM97PROKR1GAA | |
| SCHEMBL1052100 | 0.86 | F2R (0.52) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL641606 | 0.86 | F2R (0.63) | F2R | |
| SCHEMBL641532 | 0.86 | F2R (0.67) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL640599 | 0.86 | F2R (0.55) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL641085 | 0.85 | F2R (0.49) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL641841 | 0.84 | F2R (0.48) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL640711 | 0.84 | F2R (0.69) | F2RPROKR1KDM4EALDH1A1POLB | |
| SCHEMBL1056470 | 0.84 | F2R (0.39) | F2RCNR1TMEM97ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149694-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149694-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.